Compile Data Set for Download or QSAR
Report error Found 1130 of affinity data for UniProtKB/TrEMBL: P04578
TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM50002692(1-((2R,4S,5S)-4-Azido-5-hydroxymethyl-tetrahydro-f...)
Affinity DataEC50:  3nMAssay Description:The in vitro antiviral activity profile for CMX157 was evaluated for cell-type effects and HIV strain effects. It is active against all major subtype...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM77141(CMX157 ion)
Affinity DataEC50: <30nMAssay Description:The in vitro antiviral activity profile for CMX157 was evaluated for cell-type effects and HIV strain effects. It is active against all major subtype...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM77097(CMX157-210)
Affinity DataEC50: >1.00E+4nMAssay Description:The in vitro antiviral activity profile for CMX157 was evaluated for cell-type effects and HIV strain effects. It is active against all major subtype...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM77105(CMX157-211)
Affinity DataEC50: >1.00E+4nMAssay Description:The in vitro antiviral activity profile for CMX157 was evaluated for cell-type effects and HIV strain effects. It is active against all major subtype...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM77108(CMX157-220)
Affinity DataEC50: >1.00E+4nMAssay Description:The in vitro antiviral activity profile for CMX157 was evaluated for cell-type effects and HIV strain effects. It is active against all major subtype...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM50403756(CHEMBL2029048)
Affinity DataKd:  11nMAssay Description:Binding affinity towards HIV glycoprotein gp120More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM235034(2-(((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-9-(4-...)
Affinity DataEC50:  80nMAssay Description:MT-2 cells and 293T cells were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were propagated in RPMI 1640 media suppl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM235035(4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13 aR,13bR)-3a-((...)
Affinity DataEC50: <100nMAssay Description:MT-2 cells and 293T cells were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were propagated in RPMI 1640 media suppl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM235036(4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,...)
Affinity DataEC50: >100nMAssay Description:MT-2 cells and 293T cells were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were propagated in RPMI 1640 media suppl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM235037(4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13 aR,13bR)-3a-(5...)
Affinity DataEC50: >100nMAssay Description:MT-2 cells and 293T cells were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were propagated in RPMI 1640 media suppl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM235038(4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,...)
Affinity DataEC50: >100nMAssay Description:MT-2 cells and 293T cells were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were propagated in RPMI 1640 media suppl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM235039(4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(1-...)
Affinity DataEC50: >100nMAssay Description:MT-2 cells and 293T cells were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were propagated in RPMI 1640 media suppl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM235040(4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,...)
Affinity DataEC50: >100nMAssay Description:MT-2 cells and 293T cells were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were propagated in RPMI 1640 media suppl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM50281339((S)-2-{(S)-2-[(4S,9S)-9-((R)-1-Amino-2-hydroxy-eth...)
Affinity DataKd:  4.00E+3nMAssay Description:Tested for rate constant of binding to inhibit soluble recombinant CD4-gp120; value ranges form 4-20 uMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2010
Entry Details Article

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460887(US10774053, Compound 1 | US11352329, COMPD # 1)
Affinity DataEC50:  64.6nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460888(US10774053, Compound 2 | US11352329, COMPD # 2)
Affinity DataEC50:  3.00E+3nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460889(US10774053, Compound 3 | US11352329, COMPD # 3)
Affinity DataEC50:  5.71E+3nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460890(US10774053, Compound 4 | US11352329, COMPD # 4)
Affinity DataEC50:  3.62E+3nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460891(US10774053, Compound 5 | US11352329, COMPD # 5)
Affinity DataEC50:  5.71E+3nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460892(US10774053, Compound 6 | US11352329, COMPD # 6)
Affinity DataEC50:  5.71E+3nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460893(US10774053, Compound 7 | US11352329, COMPD # 7)
Affinity DataEC50:  5.71E+4nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460894(US10774053, Compound 8 | US11352329, COMPD # 8)
Affinity DataEC50:  277nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460895(US10774053, Compound 9 | US11352329, COMPD # 9)
Affinity DataEC50:  1.69E+3nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460896(US10774053, Compound 10 | US11352329, COMPD # 10)
Affinity DataEC50:  91.9nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460897(US10774053, Compound 11)
Affinity DataEC50:  35.5nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460898(US10774053, Compound 12 | US11352329, COMPD # 12)
Affinity DataEC50:  22.2nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460899(US10774053, Compound 13 | US11352329, COMPD # 13)
Affinity DataEC50:  310nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460900(US10774053, Compound 14 | US11352329, COMPD # 14)
Affinity DataEC50:  68.6nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460901(US10774053, Compound 15 | US11352329, COMPD # 15)
Affinity DataEC50:  230nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460902(US10774053, Compound 16 | US11352329, COMPD # 16)
Affinity DataEC50:  11.4nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460903(US10774053, Compound 17)
Affinity DataEC50:  556nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460904(US10774053, Compound 18 | US11352329, COMPD # 18)
Affinity DataEC50:  9.56nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460905(US10774053, Compound 19 | US11352329, COMPD # 19)
Affinity DataEC50:  49.9nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460906(US10774053, Compound 20 | US11352329, COMPD # 20)
Affinity DataEC50:  76.7nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460907(US10774053, Compound 21 | US11352329, COMPD # 21)
Affinity DataEC50:  63.8nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460909(US10774053, Compound 23 | US11352329, COMPD # 23)
Affinity DataEC50:  70.4nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460910(US10774053, Compound 24 | US11352329, COMPD # 24)
Affinity DataEC50:  68.2nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460911(US10774053, Compound 25 | US11352329, COMPD # 25)
Affinity DataEC50:  52.7nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460912(US10774053, Compound 26 | US11352329, COMPD # 27)
Affinity DataEC50:  102nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460913(US10774053, Compound 27)
Affinity DataEC50:  80.4nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460914(US10774053, Compound 28)
Affinity DataEC50:  91.7nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460915(US10774053, Compound 29 | US11352329, COMPD # 29)
Affinity DataEC50:  228nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460916(US10774053, Compound 30 | US11352329, COMPD # 30)
Affinity DataEC50:  120nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460917(BDBM556558 | US10774053, Compound 31)
Affinity DataEC50:  51nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460918(US10774053, Compound 32 | US11352329, COMPD # 32)
Affinity DataEC50:  69.2nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460919(US10774053, Compound 33 | US11352329, COMPD # 33)
Affinity DataEC50:  37.2nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460920(US10774053, Compound 34 | US11352329, COMPD # 34)
Affinity DataEC50:  38.7nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460921(US10774053, Compound 35 | US11352329, COMPD # 35)
Affinity DataEC50:  98.1nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460922(US10774053, Compound 36 | US11352329, COMPD # 36)
Affinity DataEC50:  89.3nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetEnvelope glycoprotein gp160(HIV-1)
Chimerix

US Patent
LigandPNGBDBM460923(US10774053, Compound 37 | US11352329, COMPD # 37)
Affinity DataEC50:  219nMAssay Description:Assay protocol is identical to that described for the MT-4 antiviral assay with the following changes: Each drug is run in 2 series of quadruplicates...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 1130 total ) | Next | Last >>
Jump to: